insights_auto
Waarom is LONA gestegen 4,00%?
Meer informatiechevron_right
LONA:NASDAQ
Athira Pharma
US$Â 5,98
arrow_upward
+4,00%(+0,23) 1D
7 okt, 12:00:00 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor LONA genereren…
Openen
US$Â 5,77
Hoog
US$Â 6,09
Laag
US$Â 5,61
Beursw.
56,34Â mln.
Gem. vol.
332,52K
Volume
51,26K
52 wk hoog
US$Â 14,19
52 wk laag
US$Â 2,21
WPA
US$Â -19,72
Bèta
2,11
Uitstaande aandelen
9,42Â mln.
Aantal medewerkers
19
Openen
US$Â 5,77
Hoog
US$Â 6,09
Laag
US$Â 5,61
Beursw.
56,34Â mln.
Gem. vol.
332,52K
Volume
51,26K
52 wk hoog
US$Â 14,19
52 wk laag
US$Â 2,21
WPA
US$Â -19,72
Bèta
2,11
Uitstaande aandelen
9,42Â mln.
Aantal medewerkers
19
Nieuwsartikelen
Van webbronnen en nieuwspartners
MarketScreener Nederland
·
10 minuten geleden
S&P 500 en Nasdaq nemen afstand van recordniveaus nu rentes en olie stijgen
Nieuws.nl
·
2 uur geleden
Wall Street lager na nieuwe records voor S&P 500 en Nasdaq
Invezz
·
4 uur geleden
Dow-futures dalen 305 punten: 5 dingen om te weten voor Wall Street op 7 okt.
Profiel
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Over Athira Pharma
CEO-
Medewerkers19
Opgericht2011
HoofdkantoorBothell, Washington, Verenigde Staten
Sector-
Websiteleonabio.com